Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,819 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Congenital Cardiovascular Malformation Clear all
Terminated Phase 2 Interventional Results available

Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)

NCT01467076
View directory record Official record
Conditions
Prematurity, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn
Interventions
Aerosolized Normal Saline, Inhaled PGE1
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 7 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 6, 2026, 2:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pharmacokinetics of Tranexamic Acid (TXA) in Children Undergoing Repair of Congenital Heart Defects Utilizing Cardiopulmonary Bypass

NCT01045356
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 6, 2026, 2:24 PM EDT
Completed Phase 3 Interventional

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

NCT05511922
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900 600 mg, Drug: KVD900 300 mg
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 6, 2026, 2:24 PM EDT
Completed Phase 1 Interventional

EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

NCT00056199
View directory record Official record
Conditions
Hippel-Lindau Disease
Interventions
EYE001
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 6, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema

NCT04030598
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Donidalorsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Scottsdale, Arizona • San Diego, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 6, 2026, 2:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

3D Modalities for Medical Student Education of Congenital Heart Disease

NCT07295730
View directory record Official record
Conditions
Tetralogy of Fallot (TOF), Hypoplastic Left Heart Syndrome (HLHS)
Interventions
3D-printed heart models and augmented reality
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 6, 2026, 2:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cerebrovascular Reactivity Measurements With High-Density Diffuse Optical Tomography

NCT07776444
View directory record Official record
Conditions
Sickle Cell Disease, Cerebral Stroke
Interventions
Carbon Dioxide
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 6, 2026, 2:24 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

NCT07428499
View directory record Official record
Conditions
Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
Interventions
ADX-324 Dose Level 1, ADX-324 Dose Level 2
Drug
Lead sponsor
ADARx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
15
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 6, 2026, 2:24 PM EDT
Recruiting No phase listed Observational

Bicuspid Aortic Valve Stenosis Transcatheter Aortic Valve Replacement Registry

NCT03836521
View directory record Official record
Conditions
Bicuspid Aortic Valve
Interventions
Transcatheter aortic valve replacement
Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
19 Years to 129 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 6, 2026, 2:24 PM EDT
Completed Not applicable Interventional

Improving Critical Congenital Heart Disease Screening With Addition of Perfusion Measurements

NCT04056104
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
SpO2 and PIx Measurement
Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 21 Days
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 6, 2026, 2:24 PM EDT
Completed Not applicable Interventional Results available

Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass

NCT00934843
View directory record Official record
Conditions
Congenital Heart Disease, Disorder of Fetus or Newborn
Interventions
methylprednisolone (IVMP), methylprednisolone (two doses IVMP)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
Up to 30 Days
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2011 · Synced Oct 6, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt

NCT00442364
View directory record Official record
Conditions
Varicose Veins
Interventions
Polidocanol (1%) Microfoam (Varisolve), Endovenous Microfoam Occlusion
Drug · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Los Angeles, California • Durham, North Carolina • Winston-Salem, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 6, 2026, 2:24 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

NCT05280548
View directory record Official record
Conditions
Fabry Disease
Interventions
Venglustat (GZ402671), Agalsidase alfa, Agalsidase beta (GZ419828), Migalastat
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 6, 2026, 2:24 PM EDT
Completed No phase listed Observational

Evaluating Barriers to Stroke Screening and Prevention in Children With Sickle Cell Disease

NCT03621826
View directory record Official record
Conditions
Stroke Ischemic, Sickle Cell Disease
Interventions
Questionnaire/Interview
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
2 Years to 24 Years
Enrollment
5,247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 6, 2026, 2:24 PM EDT
Completed Phase 3 Interventional

Estrogen Treatment (Oral vs. Patches) in Turner Syndrome

NCT00140998
View directory record Official record
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 beta estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years to 16 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 6, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

NCT01408732
View directory record Official record
Conditions
Epistaxis, Hereditary Hemorrhagic Telangiectasia
Interventions
Sclerotherapy, Standard Treatment
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 6, 2026, 2:24 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis

NCT02258867
View directory record Official record
Conditions
Behcet's Disease Uveitis
Interventions
Placebo, Gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Santa Ana, California • Chicago, Illinois • Ellsworth, Maine + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2015 · Synced Oct 6, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

NCT04618211
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 6, 2026, 2:24 PM EDT
Terminated Not applicable Interventional Results available

Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation

NCT02498444
View directory record Official record
Conditions
Single Ventricle
Interventions
Treprostinil
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 18 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 6, 2026, 2:24 PM EDT
Recruiting Not applicable Interventional

Bicuspid Aortic Valve Replacement: Evaluation of Transcatheter Versus Surgery-Pilot Trial

NCT06817148
View directory record Official record
Conditions
Aortic Valve Stenosis, Bicuspid Aortic Valve
Interventions
transcatheter aortic valve replacement (TAVR), surgical aortic valve replacement (SAVR)
Procedure
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
50 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 6, 2026, 2:24 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury

NCT05542238
View directory record Official record
Conditions
Spinal Cord Injuries, Cardiovascular Abnormalities, Cerebrovascular Disease; Sequelae, Cognitive Impairment
Interventions
One bout of moderate-intensity sub-maximal aerobic exercise
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 6, 2026, 2:24 PM EDT
Enrolling by invitation Phase 3 Interventional

A Long-Term Study of Navenibart in Participants With Hereditary Angioedema

NCT07204938
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
navenibart
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
10
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 6, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Results available

Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00456365
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
pravastatin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 22 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 6, 2026, 2:24 PM EDT
Recruiting No phase listed Observational

WRAP North America

NCT06807099
View directory record Official record
Conditions
Venous Stenosis, Venous Occlusion
Interventions
Merit WRAPSODY® Cell Impermeable Endoprosthesis (WRAPSODY CIE)
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
14
States / cities
Dothan, Alabama • Phoenix, Arizona • Riverside, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 6, 2026, 2:24 PM EDT